TABLE I.
Clinical characteristics of Parkinson’s disease patients for the two groups.
| Group | PD patient number | Age (years) | Sex | Handedness | Disease duration (years) | HY score | UPDRS score | Medications a |
|---|---|---|---|---|---|---|---|---|
| i | 1 | 66 | M | R | 7 | 2 | 1.0, 1.0, 1.5, 2.0 | Sel, Lev, Br |
| 2 | 75 | M | L | 8 | 2 | 0.5 | Br, Ras | |
| 3 | 75 | M | R | 6 | 3 | 3.0, 3.0 | St | |
| 4 | 49 | M | R | 8 | 3 | 3.0, 3.0, 3.0 | Lev, LevR, Sel, Ent, Rot | |
| 5 | 73 | M | R | 8 | 2 | 1.5, 2.0, 2.5 | Lev, Pr, Sel, Am | |
| 6 | 76 | M | R | 5 | 2 | 2.0, 2.0, 2.0 | Lev, Pr, Am | |
| ii | 7 | 71 | M | R | 12 | 2 | 1.0, 2.0, 3.0 | St, Rop, Sel |
| 8 | 67 | M | R | 9 | 2 | 2.0, 1.5, 2.5 | Lev, Ent, Art | |
| 9 | 68 | F | R | 11 | 3 | 1.0, 1.0, 1.5 | Lev, Pr, Ent | |
| 10 | 62 | F | R | 9 | 2 | 1.5, 1.5, 2.0 | Lev, Pr | |
| 11 | 66 | F | R | 9 | 2 | 2.0, 1.5, 1.0 | Pr, Sel, Am | |
| 12 | 70 | M | R | 24 | 3 | 1.5 | LevR, Ent, Pr, Am, Sel | |
| 13 | 67 | M | L | 8 | 3 | 2.0 | Lev, Pr, St |
a
Medication codes: Am, Amantadine; Art, Artane (trihexyphenidyl); Br, Bromocriptine; Ent, Entacapone; Lev, Carbidopa/levodopa (regular formulation); LevR, Carbidopa/levodopa sustained release; Pr, Pramipexole; Ras, Rasagiline; Rop, Ropinirole; Rot, Rotigotine; Sel, Selegiline; and St, Stalevo (Carbidopa/levodopa/entacapone).